The Norwegian injection mark study. NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The Norwegian injection mark study.

Br J Addict. 1989 Sep;84(9):1021-7. Unique Identifier : AIDSLINE MED/90001673
Skretting A; Skog OJ

Abstract: By examining persons arrested in Oslo during a certain period, we will try to obtain a better picture of intravenous drug abuse in Oslo. A pilot project was organized for 3 months during the autumn of 1987. In addition to having their arms examined, the arrestees were asked some questions about their abuse and HIV-testing. The paper presents some data from the pilot period: 35% of the arrestees had marks from intravenous drug abuse (almost 2/3 of the females and slightly less than 1/3 of the males); 78% of them were men, 22% were women; the majority were in the age range 21-35 years; 53% stated that they injected opiates, 35% that they injected stimulants and 12% that they injected both types. Nearly 80% stated that they had been HIV-tested. A larger proportion of users of opiates (88%) stated that they had been tested than users of stimulants (66%). The prevalence of HIV-seropositive cases among the arrested intravenous abusers was 13.8%. In the paper we also discuss methodological aspects of the study.
Keywords: Adolescence Adult Cross-Sectional Studies Female Human HIV Seroprevalence Incidence Male Norway/EPIDEMIOLOGY Substance Abuse Detection/*METHODS Substance Abuse, Intravenous/*EPIDEMIOLOGY JOURNAL ARTICLEKWDadolescenceadultcross-sectionalstudiesfemalehumanhivseroprevalenceincidencemalenorway/epidemiologysubstanceabusedetection/KWDmethodssubstanceabuse,intravenous/KWDepidemiologyjournalarticle
900130
M9010511

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .